Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H11Cl2N3 |
| Molecular Weight | 244.12 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(=CN=C1Cl)N2C[C@@H]3CN[C@@H]3C2
InChI
InChIKey=MBQYQLWSBRANKQ-IMTBSYHQSA-N
InChI=1S/C10H11Cl2N3/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15/h1,3,6,9,13H,2,4-5H2/t6-,9+/m0/s1
| Molecular Formula | C10H11Cl2N3 |
| Molecular Weight | 244.12 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sofinicline is a selective agonist of the a4b2 subtype of nAChR. It is under development by Abbott Laboratories in collaboration with NeuroSearch. It is produced as a capsule in doses of 1, 2 or 4 mg. Sofinicline is a full agonist of the a4b2 nAChR. It has high
binding affinity, ~ 0.1 nM, for this receptor. Sofinicline is orally active and is metabolized hepatically. Sofinicline has been used in trials studying the treatment of ADHD, neuralgia, diabetic neuropathies, diabetic polyneuropathy, and diabetic neuropathic pain, among others.
Approval Year
Sample Use Guides
Analgesic efficacy and safety of Sofinicline (ABT-894) was evaluated in 2 randomized, double-blind, multicenter, placebo-controlled clinical trials in patients with diabetic peripheral neuropathic pain (DPNP). Study 1 (280 patients randomized) tested 1, 2, and 4 mg ABT-894 twice daily compared with placebo and 60 mg duloxetine once per day over 8 weeks of treatment. Study 2 (124 patients randomized) tested 6 mg ABT-894 twice daily vs placebo for 8 weeks. A sofinicline dose of 4 mg orally twice
a day, at steady state, produced a Cmax of 11 - 15 ng/ml.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:59:13 GMT 2025
by
admin
on
Wed Apr 02 08:59:13 GMT 2025
|
| Record UNII |
SQC232V4YY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C80527
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
799279-80-4
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
DB12527
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
SQC232V4YY
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
10131048
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
DTXSID901000842
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
300000034386
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL238465
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
UU-63
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY | |||
|
9091
Created by
admin on Wed Apr 02 08:59:13 GMT 2025 , Edited by admin on Wed Apr 02 08:59:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
